• Home
  • News & IR
  • News
Company News
디엑스앤브이엑스, 사업개발·글로벌 딜 전문가 윤명진 전무 영입
2024.11.19
Company News
디엑스앤브이엑스 "'MEDICA 2024'서 유럽시장 판로 모색"
2024.11.18
Company News
디엑스앤브이엑스 "'MEDICA 2024'서 유럽시장 판로 모색"
2024.11.18
Company News
디엑스앤브이엑스, mRNA 백신 한계 극복 기술 개발
2024.11.01
Company News
DXVX Develops Groundbreaking Technology to Overcome mRNA Vaccine Storage Limitations Verifies Possibility of Room-Temperature Storage for Over 10 Years Through Preliminary Research
2024.11.01
Company News
DX&VX Selected for Korea's First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology
2024.11.01
Company News
Dx&Vx, ‘상온 초장기 비축 mRNA백신소재 및 대량생산 공정기술 개발’ 국책과제 선정
2024.10.30
Company News
Dx&Vx, 'Room temperature ultra-long-term stockpiling mRNA vaccine material and mass production process technology development' selected as national projec
2024.10.30
Company News
DXVX, ‘상온 초장기 비축 mRNA 백신 소재 및 대량 생산 공정 기술 개발’ 국책과제 선정
2024.10.30
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8.   
  • 10F, 173, Digital-ro, Geumcheon-gu, Seoul (Gasan-dong, Elysian)
  • Tel : 02-890-8700
  • IR Service : 02-6964-8770
  • Fax : 02-6964-8755

About Us

Goals & Promise

Leadership

Company History

IR

Notice & IR

Disclosure Information

Dx&Vx 2023 Award Impact

Contact

Private Policy Terms of Use twitter icon @dxvx_official
© 2024 Dx&Vx. All Rights Reserved.